The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Nanoparticle‐Enhanced Radiotherapy to Trigger Robust Cancer Immunotherapy
Abstract
External radiotherapy is extensively used in clinic to destruct tumors by locally applied ionizing‐radiation beams. However, the efficacy of radiotherapy is usually limited by tumor hypoxia‐associated radiation resistance. Moreover, as a local treatment technique, radiotherapy can hardly control tumor metastases, the major cause of cancer death. Herein, core–shell nanoparticles based poly(lactic‐co‐glycolic) acid (PLGA) are fabricate, by encapsulating water‐soluble catalase (Cat), an enzyme that can decompose H 2 O 2 to generate O 2, inside the inner core, and loading hydrophobic imiquimod (R837), a Toll‐like‐receptor‐7 agonist, within the PLGA shell. The formed PLGA‐R837@Cat nanoparticles can greatly enhance radiotherapy efficacy by relieving the tumor hypoxia and modulating the immune‐suppressive tumor microenvironment. The tumor‐associated antigens generated postradiotherapy‐induced immunogenic cell death in the presence of such R837‐loaded adjuvant nanoparticles will induce strong antitumor immune responses, which together with cytotoxic T‐lymphocyte associated protein 4 (CTLA‐4) checkpoint blockade will be able to effectively inhibit tumor metastases by a strong abscopal effect. Moreover, a long term immunological memory effect to protect mice from tumor rechallenging is observed post such treatment. This work thus presents a unique nanomedicine approach as a next‐generation radiotherapy strategy to enable synergistic whole‐body therapeutic responses after local treatment, greatly promising for clinical translation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
Sallusto, F., Lenig, D., Förster, R., Lipp, M., & Lanzavecchia, A. (1999) · Nature · doi:10.1038/44385 · Cited by 5,846
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
A simple method for determination of serum catalase activity and revision of reference range
Góth, L. (1991) · Clinica Chimica Acta · doi:10.1016/0009-8981(91)90067-m · Cited by 2,385
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
Thermal ablation of tumours: biological mechanisms and advances in therapy
Chu, K. F., & Dupuy, D. E. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3672 · Cited by 1,988
Effector and memory T-cell differentiation: implications for vaccine development
Kaech, S. M., Wherry, E. J., & Ahmed, R. (2002) · Nature Reviews Immunology · doi:10.1038/nri778 · Cited by 1,865
Lineage relationship and protective immunity of memory CD8 T cell subsets
Wherry, E. J., Teichgräber, V., Becker, T. C., Masopust, D., Kaech, S. M., Antia, R., von Andrian, U. H., & Ahmed, R. (2003) · Nature Immunology · doi:10.1038/ni889 · Cited by 1,864
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
Vanpouille-Box, C., Alard, A., Aryankalayil, M. J., Sarfraz, Y., Diamond, J. M., Schneider, R. J., Inghirami, G., Coleman, C. N., Formenti, S. C., & Demaria, S. (2017) · Nature Communications · doi:10.1038/ncomms15618 · Cited by 1,834
Kägi, D., Ledermann, B., Bürki, K., Seiler, P., Odermatt, B., Olsen, K. J., Podack, E. R., Zinkernagel, R. M., & Hengartner, H. (1994) · Nature · doi:10.1038/369031a0 · Cited by 1,757
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., & Dudley, M. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2355 · Cited by 1,659
Chen, Q., Xu, L., Liang, C., Wang, C., Peng, R., & Liu, Z. (2016) · Nature Communications · doi:10.1038/ncomms13193 · Cited by 1,596
Self-citationYang, G., Xu, L., Chao, Y., Xu, J., Sun, X., Wu, Y., Peng, R., & Liu, Z. (2017) · Nature Communications · doi:10.1038/s41467-017-01050-0 · Cited by 1,477
Self-citationHigh-intensity focused ultrasound in the treatment of solid tumours
Kennedy, J. E. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1591 · Cited by 1,282
Antitumor and antimetastatic activity of interleukin 12 against murine tumors.
Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F., & Gately, M. K. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.4.1223 · Cited by 1,197
Strategies to improve radiotherapy with targeted drugs
Begg, A. C., Stewart, F. A., & Vens, C. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3007 · Cited by 1,118
An Antimicrobial Activity of Cytolytic T Cells Mediated by Granulysin
Stenger, S., Hanson, D. A., Teitelbaum, R., Dewan, P., Niazi, K. R., Froelich, C. J., Ganz, T., Thoma-Uszynski, S., Melián, A., Bogdan, C., et al. (1998) · Science · doi:10.1126/science.282.5386.121 · Cited by 1,065
Signals and signs for lymphocyte responses
Janeway, C. A., & Bottomly, K. (1994) · Cell · doi:10.1016/0092-8674(94)90335-2 · Cited by 848
T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis
Facciabene, A., Motz, G. T., & Coukos, G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3687 · Cited by 821
Chen, H., Tian, J., He, W., & Guo, Z. (2015) · Journal of the American Chemical Society · doi:10.1021/ja511420n · Cited by 813
Emerging Nanotechnology and Advanced Materials for Cancer Radiation Therapy
Song, G., Cheng, L., Chao, Y., Yang, K., & Liu, Z. (2017) · Advanced Materials · doi:10.1002/adma.201700996 · Cited by 771
Self-citationDuraiswamy, J., Kaluza, K. M., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4100 · Cited by 745
Bertrand, A., Kostine, M., Barnetche, T., Truchetet, M.-E., & Schaeverbeke, T. (2015) · BMC Medicine · doi:10.1186/s12916-015-0455-8 · Cited by 704
Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy
Min, Y., Roche, K. C., Tian, S., Eblan, M. J., McKinnon, K. P., Caster, J. M., Chai, S., Herring, L. E., Zhang, L., Zhang, T., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.113 · Cited by 701
Xu, J., Xu, L., Wang, C., Yang, R., Zhuang, Q., Han, X., Dong, Z., Zhu, W., Peng, R., & Liu, Z. (2017) · ACS Nano · doi:10.1021/acsnano.7b00715 · Cited by 695
Self-citationImmunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M., & Chen, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2051 · Cited by 627
Song, G., Liang, C., Yi, X., Zhao, Q., Cheng, L., Yang, K., & Liu, Z. (2016) · Advanced Materials · doi:10.1002/adma.201504617 · Cited by 587
Self-citationWang, C., Xu, L., Liang, C., Xiang, J., Peng, R., & Liu, Z. (2014) · Advanced Materials · doi:10.1002/adma.201402996 · Cited by 566
Self-citationIn situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy
Wang, C., Sun, W., Ye, Y., Hu, Q., Bomba, H. N., & Gu, Z. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-016-0011 · Cited by 526
Zhang, C., Zhao, K., Bu, W., Ni, D., Liu, Y., Feng, J., & Shi, J. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201408472 · Cited by 516
Chemical Radiosensitizers for Use in Radiotherapy
Wardman, P. (2007) · Clinical Oncology · doi:10.1016/j.clon.2007.03.010 · Cited by 447
Lu, J., Liu, X., Liao, Y.-P., Salazar, F., Sun, B., Jiang, W., Chang, C. H., Jiang, J., Wang, X., Wu, A. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01651-9 · Cited by 440
Wang, D., Wang, T., Liu, J., Yu, H., Jiao, S., Feng, B., Zhou, F., Fu, Y., Yin, Q., Zhang, P., et al. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b01994 · Cited by 405
Song, G., Chen, Y., Liang, C., Yi, X., Liu, J., Sun, X., Shen, S., Yang, K., & Liu, Z. (2016) · Advanced Materials · doi:10.1002/adma.201602111 · Cited by 394
Self-citationGranzymes: exogenous porteinases that induce target cell apoptosis
Smyth, M. J., & Trapani, J. A. (1995) · Immunology Today · doi:10.1016/0167-5699(95)80122-7 · Cited by 389
A melanin-mediated cancer immunotherapy patch
Ye, Y., Wang, C., Zhang, X., Hu, Q., Zhang, Y., Liu, Q., Wen, D., Milligan, J., Bellotti, A., Huang, L., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aan5692 · Cited by 381
Xu, Z., Wang, Y., Zhang, L., & Huang, L. (2014) · ACS Nano · doi:10.1021/nn500216y · Cited by 284
Potent Induction of Tumor Immunity by Combining Tumor Cryoablation with Anti–CTLA-4 Therapy
Waitz, R., Solomon, S. B., Petre, E. N., Trumble, A. E., Fassò, M., Norton, L., & Allison, J. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1782 · Cited by 282
Different T Cell Receptor Signals Determine CD8 + Memory Versus Effector Development
Teixeiro, E., Daniels, M. A., Hamilton, S. E., Schrum, A. G., Bragado, R., Jameson, S. C., & Palmer, E. (2009) · Science · doi:10.1126/science.1163612 · Cited by 199
In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment
Vanpouille-Box, C., Pilones, K. A., Wennerberg, E., Formenti, S. C., & Demaria, S. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.05.105 · Cited by 177
Real-time tracking of cell cycle progression during CD8+ effector and memory T-cell differentiation
Kinjyo, I., Qin, J., Tan, S., Wellard, C. J., Mrass, P., Ritchie, W., Doi, A., Cavanagh, L. L., Tomura, M., Sakaue-Sawano, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7301 · Cited by 154
Xu, L., Liu, Y., Chen, Z., Li, W., Liu, Y., Wang, L., Ma, L., Shao, Y., Zhao, Y., & Chen, C. (2013) · Advanced Materials · doi:10.1002/adma.201300583 · Cited by 142
Self-citationCancer Immunotherapy via Dendritic Cells
Palucka, K., & Banchereau, J. (2013) · Springer eBooks · doi:10.1007/978-3-7091-1300-4_4 · Cited by 128
Cutting Edge: Latecomer CD8 T Cells Are Imprinted with a Unique Differentiation Program
D’Souza, W. N., & Hedrick, S. Μ. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.2.777 · Cited by 126
Yoshimoto, Y., Suzuki, Y., Mimura, K., Ando, K., Oike, T., Sato, H., Okonogi, N., Maruyama, T., Izawa, S., Noda, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092572 · Cited by 126
Chen, Q., Xu, L., Chen, J., Yang, Z., Liang, C., Yang, Y., & Liu, Z. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.021 · Cited by 104
Self-citationRationale and clinical application of alkylphospholipid analogues in combination with radiotherapy
Vink, S. R., BLITTERSWIJK, W. J. V., Schellens, J. H. M., & Verheij, M. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.12.001 · Cited by 94
Clinical Application of Image-guided Radiotherapy in Bladder and Prostate Cancer
Button, M., & Staffurth, J. N. (2010) · Clinical Oncology · doi:10.1016/j.clon.2010.06.020 · Cited by 59
Almeida, J. P. M., Drezek, R. A., & Foster, A. E. (2014) · Immunotherapy · doi:10.2217/imt.13.158 · Cited by 11
Cited by
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
Martin, J. D., Cabral, H., Stylianopoulos, T., & Jain, R. K. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0308-z · Cited by 682
Li, Z., Lai, X., Fu, S., Ren, L., Cai, H., Zhang, H., Gu, Z., Ma, X., & Luo, K. (2022) · Advanced Science · doi:10.1002/advs.202201734 · Cited by 680
Yang, B., Chen, Y., & Shi, J. (2019) · Advanced Materials · doi:10.1002/adma.201901778 · Cited by 601
Chen, C., Ni, X., Jia, S., Liang, Y., Wu, X., Kong, D., & Ding, D. (2019) · Advanced Materials · doi:10.1002/adma.201904914 · Cited by 503
Tumor‐Microenvironment‐Responsive Nanomedicine for Enhanced Cancer Immunotherapy
Peng, S., Xiao, F., Chen, M., & Gao, H. (2022) · Advanced Science · doi:10.1002/advs.202103836 · Cited by 441
Metadata
- Authors
- Chen, Q., Chen, J., Yang, Z., Xu, J., Xu, L., Liang, C., Han, X., & Liu, Z.
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2019-01-21
- Volume
- 31
- Issue
- 10
- Pages
- e1802228-e1802228
- ISSN
- 0935-9648 (ISSN-L)
- 1521-4095
- OpenAlex
- W2908838385
- Cited by
- 661
- References
- 58
- FWCI
- 30.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.